Hydroxyurea Continues to Lower Hospitalizations in Children with Sickle Cell Anemia, Study Confirms

A new study indicates that hydroxyurea continues to effectively decrease hospital visits for children who have sickle cell anemia. The research supports the continued use of hydroxyurea as a standard treatment option for this patient population. Researchers observed the long-term effects of hydroxyurea on children with sickle cell anemia and found a sustained reduction in the frequency of hospitalizations. The findings suggest that the drug maintains its effectiveness over time, reinforcing its role in managing the complications associated with the disease. These results add to the existing body of evidence supporting hydroxyurea as a beneficial treatment for reducing the burden of sickle cell anemia in children.

Newsflash | Powered by GeneOnline AI
Date: April 26, 2025

Related posts:

FDA Approves Gene Therapy for Dystrophic Epidermolysis Bullosa, Targeting Large and Chronic Wounds FDA Accepts Novo Nordisk NDA for 25 mg Oral Wegovy Semaglutide Resolves MASH in 62.9% of Patients Without Worsening Fibrosis, Study Finds Pharmaceutical Collaboration Commits Up to $250 Million Over Eight Years; CRISPR Therapeutics Releases Data; Vivo Capital Closes Funding Round

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後